OBJECTIVE: Male circumcision reduces female-to-male HIV-1 transmission risk by approximately 60%. Data assessing the effect of circumcision on male-to-female HIV-1 transmission are conflicting, with one observational study among HIV-1-serodiscordant couples showing reduced transmission but a randomized trial suggesting no short-term benefit of circumcision. DESIGN/ METHODS: Data collected as part of a prospective study among African HIV-1-serodiscordant couples were analyzed for the relationship between circumcision status of HIV-1-seropositive men and risk of HIV-1 acquisition among their female partners. Circumcision status was determined by physical examination. Cox proportional hazards analysis was used. RESULTS: A total of 1096 HIV-1-serodiscordant couples in which the male partner was HIV-1-infected were followed for a median of 18 months; 374 (34%) male partners were circumcised. Sixty-four female partners seroconverted to HIV-1 (incidence 3.8 per 100 person-years). Circumcision of the male partner was associated with a nonstatistically significant approximately 40% lower risk of HIV-1 acquisition by the female partner (hazard ratio 0.62, 95% confidence interval 0.35-1.10, P = 0.10). The magnitude of this effect was similar when restricted to the subset of HIV-1 transmission events confirmed by viral sequencing to have occurred within the partnership (n = 50, hazard ratio 0.57, P = 0.11), after adjustment for male partner plasma HIV-1 concentrations (hazard ratio 0.60, P = 0.13), and when excluding follow-up time for male partners who initiated antiretroviral therapy (hazard ratio 0.53, P = 0.07). CONCLUSION: Among HIV-1-serodiscordant couples in which the HIV-1-seropositive partner was male, we observed no increased risk and potentially decreased risk from circumcision on male-to-female transmission of HIV-1.
OBJECTIVE: Male circumcision reduces female-to-male HIV-1 transmission risk by approximately 60%. Data assessing the effect of circumcision on male-to-female HIV-1 transmission are conflicting, with one observational study among HIV-1-serodiscordant couples showing reduced transmission but a randomized trial suggesting no short-term benefit of circumcision. DESIGN/ METHODS: Data collected as part of a prospective study among African HIV-1-serodiscordant couples were analyzed for the relationship between circumcision status of HIV-1-seropositivemen and risk of HIV-1 acquisition among their female partners. Circumcision status was determined by physical examination. Cox proportional hazards analysis was used. RESULTS: A total of 1096 HIV-1-serodiscordant couples in which the male partner was HIV-1-infected were followed for a median of 18 months; 374 (34%) male partners were circumcised. Sixty-four female partners seroconverted to HIV-1 (incidence 3.8 per 100 person-years). Circumcision of the male partner was associated with a nonstatistically significant approximately 40% lower risk of HIV-1 acquisition by the female partner (hazard ratio 0.62, 95% confidence interval 0.35-1.10, P = 0.10). The magnitude of this effect was similar when restricted to the subset of HIV-1 transmission events confirmed by viral sequencing to have occurred within the partnership (n = 50, hazard ratio 0.57, P = 0.11), after adjustment for male partner plasma HIV-1 concentrations (hazard ratio 0.60, P = 0.13), and when excluding follow-up time for male partners who initiated antiretroviral therapy (hazard ratio 0.53, P = 0.07). CONCLUSION: Among HIV-1-serodiscordant couples in which the HIV-1-seropositive partner was male, we observed no increased risk and potentially decreased risk from circumcision on male-to-female transmission of HIV-1.
Authors: T C Quinn; M J Wawer; N Sewankambo; D Serwadda; C Li; F Wabwire-Mangen; M O Meehan; T Lutalo; R H Gray Journal: N Engl J Med Date: 2000-03-30 Impact factor: 91.245
Authors: Ronald H Gray; Godfrey Kigozi; David Serwadda; Frederick Makumbi; Stephen Watya; Fred Nalugoda; Noah Kiwanuka; Lawrence H Moulton; Mohammad A Chaudhary; Michael Z Chen; Nelson K Sewankambo; Fred Wabwire-Mangen; Melanie C Bacon; Carolyn F M Williams; Pius Opendi; Steven J Reynolds; Oliver Laeyendecker; Thomas C Quinn; Maria J Wawer Journal: Lancet Date: 2007-02-24 Impact factor: 79.321
Authors: Robert C Bailey; Stephen Moses; Corette B Parker; Kawango Agot; Ian Maclean; John N Krieger; Carolyn F M Williams; Richard T Campbell; Jeckoniah O Ndinya-Achola Journal: Lancet Date: 2007-02-24 Impact factor: 79.321
Authors: Oliver Laeyendecker; Charla Henson; Ronald H Gray; Ruby H-N Nguyen; Bobbi Jo Horne; Maria J Wawer; David Serwadda; Noah Kiwanuka; Rhoda Ashley Morrow; Wayne Hogrefe; Thomas C Quinn Journal: J Clin Microbiol Date: 2004-04 Impact factor: 5.948
Authors: Nancy S Padian; Sandra I McCoy; Salim S Abdool Karim; Nina Hasen; Julia Kim; Michael Bartos; Elly Katabira; Stefano M Bertozzi; Bernhard Schwartländer; Myron S Cohen Journal: Lancet Date: 2011-07-16 Impact factor: 79.321
Authors: Brian J Morris; Robert C Bailey; Jeffrey D Klausner; Arleen Leibowitz; Richard G Wamai; Jake H Waskett; Joya Banerjee; Daniel T Halperin; Laurie Zoloth; Helen A Weiss; Catherine A Hankins Journal: AIDS Care Date: 2012-03-28
Authors: Connie Celum; Jared M Baeten; James P Hughes; Ruanne Barnabas; Albert Liu; Heidi Van Rooyen; Susan Buchbinder Journal: J Acquir Immune Defic Syndr Date: 2013-07 Impact factor: 3.731